CANBAS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 448 JPY | -3.03% |
|
+0.45% | -53.33% |
| 2023 | CanBas Co., Ltd.(TSE:4575) added to S&P Global BMI Index | CI |
| 2023 | CanBas Co., Ltd. announced that it has received ¥748.0425 million in funding | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 20.13B 127M 10.6B |
|---|---|---|---|---|---|
| Net income 2022 | -855M -5.4M -450M | Net income 2023 | -1.24B -7.85M -655M | EV / Sales 2022 | - |
| Net cash position 2022 | 370M 2.34M 195M | Net cash position 2023 | 1.62B 10.21M 851M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-7.35
x | P/E ratio 2023 |
-14.8
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.85% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.03% | ||
| 1 week | +0.45% | ||
| Current month | -4.88% | ||
| 1 month | -8.94% | ||
| 3 months | -50.00% | ||
| 6 months | -51.62% | ||
| Current year | -53.33% |
1 week
446.00
482.00
1 month
429.00502.00
Current year
411.001 039.00
1 year
411.001 666.00
3 years
162.002 975.00
5 years
162.002 975.00
10 years
162.002 975.00
| Managers | Title | Age | Since |
|---|---|---|---|
Takumi Kawabe
FOU | Founder | 65 | 18/00/18 |
Makoto Katozumi
DFI | Director of Finance/CFO | 60 | 01/00/01 |
| Chief Administrative Officer | 61 | 01/08/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takumi Kawabe
FOU | Founder | 65 | 18/00/18 |
Makoto Katozumi
DFI | Director of Finance/CFO | 60 | 01/00/01 |
Kyoko Matsuzaki
BRD | Director/Board Member | 74 | 01/03/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 448 | -3.03% | 229,500 |
| 25/24/25 | 462 | +1.32% | 300,200 |
| 24/24/24 | 456 | -0.87% | 229,100 |
| 23/24/23 | 460 | -0.43% | 89,500 |
| 22/24/22 | 462 | +3.59% | 267,000 |
Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST
More quotes
CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).
Sector
Pharmaceuticals
Calendar
10/05/2024
- Q3 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -53.33% | 51.29M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- 4575 Stock
